Results 111 to 120 of about 15,116 (246)

Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses

open access: yesBrain Sciences
The acute levodopa challenge is widely used to distinguish Parkinson’s disease (PD) from atypical parkinsonian syndromes (APSs) such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).
Lan Ye   +8 more
doaj   +1 more source

Through the body into the brain: The pathway of Levodopa in Parkinson's disease

open access: yes
reservedLa Levodopa rappresenta da sempre il trattamento farmacologico di base adoperato al fine di gestire e contrastare la progressione sintomatica della malattia di Parkinson.
D'AUGUSTA PERNA, CHIARA
core  

Socio‐Occupational Functioning after Subthalamic Deep Brain Stimulation in Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Socio‐occupational functioning in patients with Parkinson's disease (PD) treated with subthalamic nucleus deep brain stimulation (STN‐DBS) is not fully captured by standard motor and quality‐of‐life scales. Objectives To characterize patient‐reported socio‐occupational functioning after STN‐DBS and explore associated clinical and ...
Gabriele Imbalzano   +7 more
wiley   +1 more source

Treatment of Levodopa induced motor complications with continuous Levodopa/Carbidopa in Parkinson's disease

open access: yes, 2023
Parkinson's disease is a neurodegenerative disorder characterized by the degenerationdopamine-producingcing neurons. The gold standard therfory of the diseasethe is administration of levodopa/cawhichopa that aims to replenish the missing dopamine in the
Adam Dagan, Shaked
core  

Asymmetric Upper Limb Dysfunction Demonstrated at the Bedside: A Phenomenology Video

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Gero Lueg   +4 more
wiley   +1 more source

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats

open access: yesDrug Design, Development and Therapy, 2012
Xinxin Yang,1,* Yinghui Chen,2,* Xiaoyun Hong,3 Na Wu,1 Lu Song,1 Weien Yuan,3 Zhenguo Liu11Department of Neurology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China; 2Department of Neurology, Jinshan ...
Song L,Yuan W   +5 more
doaj  

Early Cervical and Orofacial Variable Dystonia in Levodopa‐Naïve PRKN Parkinson's Disease

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Amy Gallagher   +6 more
wiley   +1 more source

Sex Differences in Fall Frequency, Risk Factors, and Outcomes in Parkinson's Disease: A Cross‐Sectional Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Female sex is an independent fall risk factor in Parkinson's disease (PD), yet sex‐specific fall patterns remain unclear. Objectives To compare sex‐specific fall risk and outcomes across PD, prodromal alpha‐synucleinopathy (PAS), and healthy controls (HC); estimate fall frequency across PD progression; and assess how sex modifies ...
Joaquin A. Vizcarra   +197 more
wiley   +1 more source

Impact of Istradefylline on Levodopa Dose Escalation in Parkinson’s Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study

open access: yesNeurology and Therapy
Introduction A higher levodopa dose is a risk factor for motor complications in Parkinson’s disease (PD). Istradefylline (IST) is used as adjunctive treatment to levodopa in PD patients with off episodes, but its impact on levodopa dose titration remains
Taku Hatano   +28 more
doaj   +1 more source

Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up

open access: yes, 2017
Objectives To report the results of a national survey aimed at quantifying the current level of diffusion of Levodopa/carbidopa intestinal gel (LCIG) in Italy.
Italian Levodopa Carbidopa Intestinal Gel Working Group [. . .   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy